Reuters logo
BRIEF-Abivax enrolls first ulcerative colitis patient in ABX464 trial
November 20, 2017 / 7:18 AM / 21 days ago

BRIEF-Abivax enrolls first ulcerative colitis patient in ABX464 trial

Nov 20 (Reuters) - ABIVAX SA

* ABIVAX ENROLLS FIRST ULCERATIVE COLITIS PATIENT IN NEW ABX464 PROOF-OF-CONCEPT CLINICAL TRIAL

* ‍PHASE 2A TRIAL TRIGGERS EXPANSION OF ABX464 TO INFLAMMATORY INDICATIONS​

* ‍LONG TERM PROTOCOL FOR OPEN-LABEL FOLLOW-UP STUDY PLANNED​

* ‍REGULATORY AUTHORIZATIONS RECEIVED IN BELGIUM, HUNGARY AND FRANCE​

* ‍TOP-LINE DATA ARE EXPECTED TO BE REPORTED IN SECOND HALF OF 2018​

* ‍FIRST PATIENT WAS ENROLLED THIS WEEK AT UNIVERSITY HOSPITALS LEUVEN, BELGIUM​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below